Daiichi Sankyo posts 11.4% jump in first-quarter sales

Headline results for the first quarter:

  • Revenue: JPY 264.1 billion ($2.4 billion), up 11.4%
  • Profit: JPY 35.2 billion ($321 million), up 10.7%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

Daiichi Sankyo said revenues during the first quarter were boosted by growth from the iron replacement therapy Injectafer, which had been negatively impacted by the spread of COVID-19 last year along with other drugs, as well as gains from global mainstay products Lixiana and Enhertu.

Other results:

  • Oncology unit sales: JPY 14.5 billion ($132 million), up 25.1%
    • Enhertu: JPY 10.8 billion ($98 million), up 116.1%, showing "steady growth" in the US and Japan, and expansion into Europe where it was launched starting late last year for third-line HER2+ breast cancer
    • Turalio: JPY 600 million ($5 million), up 85.4%
  • American reagent business unit sales: JPY 39.1 billion ($356 million), up 47.7%
    • Injectafer: JPY 14.9 billion ($136 million), up 57.7%
  • EU speciality business unit sales: JPY 32.7 billion ($298 million), up 18.1%
    • Lixiana: JPY 23.4 billion ($213 million), up 42.4%
    • Olmesartan: JPY 5.6 billion ($51 million), up 7.3%
  • Japan unit sales: JPY 129.1 billion ($1.2 billion), down 0.8%
  • ASCA (Asia, South and Central America) unit sales: JPY 26.5 billion ($241 million), up 17.4%
    • China: JPY 11.8 billion ($107 million), up 36.5%

 Looking ahead:

Daiichi Sankyo is maintaining its forecast for the fiscal year ending March 2022 of JPY 50 billion ($455 million) in profit, which represents a decline of 34.1% year-over-year, on revenues of JPY 990 billion ($9 billion), reflecting a gain of 2.9% over the previous fiscal.

Pipeline update:

The company noted that aside from terminating the nafamostat inhalation formulation, dubbed DS-2319, for the treatment of COVID-19 last month, it has also discontinued development of the anti-ORAI1 antibody DS-2741 in atopic dermatitis.

To read more Top Story articles, click here.